Lisa-Beth Ferstenberg, M.D.
Dr. Lisa Beth Ferstenberg, MD, is a seasoned biopharmaceutical entrepreneur with 35 years of experience developing products for cancer, immunology and infectious diseases, including new drugs, vaccines, targeted immunotherapies, stem cell therapies and biotech innovations. She was founding CEO of Cellective Therapeutics, Inc., a venture backed company that developed a monoclonal antibody for autoimmune indications, which was acquired by MedImmune. Lisa Beth has also been founding CEO of two other ventures, including an anticancer product and a Contract Research Organization with successful exits. Her core expertise is the development of clinical/ regulatory strategies for product approval. She frequently oversees pharmacovigilance aspects of on-going clinical trials, serving as Medical Monitor.